ES2613698T3 - Combinación, kit y método de reducción de la presión intraocular - Google Patents
Combinación, kit y método de reducción de la presión intraocular Download PDFInfo
- Publication number
- ES2613698T3 ES2613698T3 ES11732309.7T ES11732309T ES2613698T3 ES 2613698 T3 ES2613698 T3 ES 2613698T3 ES 11732309 T ES11732309 T ES 11732309T ES 2613698 T3 ES2613698 T3 ES 2613698T3
- Authority
- ES
- Spain
- Prior art keywords
- intraocular pressure
- combination
- kit
- pressure reduction
- dihydroxytetrahydrofuran
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
Abstract
Una combinación oftálmica que comprende i)**Fórmula** ((2R,3S,4R,5R)-5-(6-(ciclopentilamino)-9H-purin-9-il)-3,4-dihidroxitetrahidrofuran-2-il)metil nitrato, o una sal farmacéuticamente aceptable del mismo, y ii) un compuesto seleccionado entre el grupo que consiste en latanoprost, travoprost, unoprostona y bimatoprost, para su uso en la reducción de la presión intraocular elevada en un ojo de un sujeto.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29380610P | 2010-01-11 | 2010-01-11 | |
US293806P | 2010-01-11 | ||
PCT/US2011/020808 WO2011085361A1 (en) | 2010-01-11 | 2011-01-11 | Combination, kit and method of reducing intraocular pressure |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2613698T3 true ES2613698T3 (es) | 2017-05-25 |
Family
ID=44258984
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES11732309.7T Active ES2613698T3 (es) | 2010-01-11 | 2011-01-11 | Combinación, kit y método de reducción de la presión intraocular |
Country Status (28)
Country | Link |
---|---|
US (3) | US8877732B2 (es) |
EP (1) | EP2523669B1 (es) |
JP (2) | JP2013516495A (es) |
KR (1) | KR20120115344A (es) |
CN (1) | CN102711771B (es) |
AU (1) | AU2011203897B2 (es) |
BR (1) | BR112012017106A2 (es) |
CA (1) | CA2784908A1 (es) |
CL (1) | CL2012001912A1 (es) |
CO (1) | CO6571924A2 (es) |
CY (1) | CY1118510T1 (es) |
DK (1) | DK2523669T3 (es) |
EA (1) | EA025415B1 (es) |
ES (1) | ES2613698T3 (es) |
HR (1) | HRP20170007T1 (es) |
HU (1) | HUE030566T2 (es) |
IL (1) | IL220604A (es) |
IN (1) | IN2012DN06592A (es) |
LT (1) | LT2523669T (es) |
ME (1) | ME02608B (es) |
MX (1) | MX2012007661A (es) |
PL (1) | PL2523669T3 (es) |
PT (1) | PT2523669T (es) |
RS (1) | RS55615B1 (es) |
SG (2) | SG182285A1 (es) |
SI (1) | SI2523669T1 (es) |
SM (1) | SMT201700017B (es) |
WO (1) | WO2011085361A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA024042B1 (ru) * | 2009-05-01 | 2016-08-31 | Инотек Фармасьютикалз Корпорейшн | Способ снижения внутриглазного давления у людей |
AU2011203897B2 (en) * | 2010-01-11 | 2016-11-17 | Inotek Pharmaceuticals Corporation | Combination, kit and method of reducing intraocular pressure |
US8476247B2 (en) | 2010-03-26 | 2013-07-02 | Inotek Pharmaceuticals Corporation | Method of reducing intraocular pressure in humans |
SG11201403979TA (en) * | 2012-01-26 | 2014-08-28 | Inotek Pharmaceuticals Corp | Anhydrous polymorphs of (2r,3s,4r,5r)-5-(6-(cyclopentylamino)-9h-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl) } methyl nitrate and processes of preparation thereof |
AU2014239232A1 (en) * | 2013-03-15 | 2015-10-01 | Inotek Pharmaceuticals Corporation | A method of providing ocular neuroprotection |
WO2014152723A1 (en) | 2013-03-15 | 2014-09-25 | Inotek Pharmaceuticals Corporation | Ophthalmic formulations |
BR112017008178A2 (pt) | 2014-10-24 | 2017-12-19 | Ono Pharmaceutical Co | ativador do canal de kcnq2-5 |
CN107406479A (zh) * | 2014-12-03 | 2017-11-28 | 伊诺泰克制药公司 | 预防、减轻或治疗黄斑变性的方法 |
Family Cites Families (107)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4935635B1 (es) | 1970-12-28 | 1974-09-25 | ||
CH563405A5 (es) | 1971-09-10 | 1975-06-30 | Duschinsky Robert Dr Schweiz I | |
DE2226295A1 (de) | 1972-05-30 | 1973-12-20 | Henning Berlin Gmbh | Salpetersaeureester von purinnucleosiden und verfahren zur herstellung derselben |
DE2342479A1 (de) | 1973-08-23 | 1975-03-13 | Merck Patent Gmbh | Ribonucleosid-5'-nitrate und verfahren zu ihrer herstellung |
GB2001976B (en) | 1977-08-03 | 1982-03-10 | Yamasa Shoyu Kk | S-adenosyl-l-methionine compositions and production thereof |
US4849311A (en) | 1986-09-24 | 1989-07-18 | Toa Nenryo Kogyo Kabushiki Kaisha | Immobilized electrolyte membrane |
US4968697A (en) | 1987-02-04 | 1990-11-06 | Ciba-Geigy Corporation | 2-substituted adenosine 5'-carboxamides as antihypertensive agents |
US5219840A (en) | 1987-04-06 | 1993-06-15 | Sandoz Ltd. | Antihypertensive 9-(2,N6 -disubstituted adenyl) ribofuranuronic acid derivatives |
US5221763A (en) * | 1987-04-30 | 1993-06-22 | R-Tech Ueno, Ltd. | Prostaglandins of the F series |
US5591887A (en) * | 1987-04-30 | 1997-01-07 | R-Tech Ueno, Ltd. | Prostaglandins of the F series |
DE68913000T3 (de) | 1988-09-06 | 2004-10-21 | Pharmacia Ab | Prostaglandinderivate zur Behandlung des grünen Stars oder einer okularen Hypertension. |
US6187813B1 (en) | 1990-04-10 | 2001-02-13 | Pharmacia & Upjohn Aktiebolag | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
US5296504A (en) | 1988-09-06 | 1994-03-22 | Kabi Pharmacia | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
US5140015A (en) | 1990-02-20 | 1992-08-18 | Whitby Research, Inc. | 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents |
US5280015A (en) | 1990-09-05 | 1994-01-18 | The United States Of America As Represented By The Department Of Health And Human Services | 2-substituted adenosines and 2-substituted adenosine 5'-carboxamides |
JP3020580B2 (ja) | 1990-09-28 | 2000-03-15 | 株式会社日立製作所 | マイクロ波プラズマ処理装置 |
US5206222A (en) | 1991-05-22 | 1993-04-27 | Vanderbilt University | Methods for the reduction of myocardial reperfusion injury |
HU212570B (en) * | 1991-06-24 | 1996-08-29 | Chinoin Gyogyszer Es Vegyeszet | Process for producing 13,14-dihydro-15(r)-17-phenyl-18,19,20-trinor-pgf2alfa-isopropylester |
US5407793A (en) | 1991-10-18 | 1995-04-18 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | An aqueous heart preservation and cardioplegia solution |
US5278150A (en) | 1992-04-24 | 1994-01-11 | Whitby Research, Inc. | 2-hydrazoadenosines and their utility for the treatmeat of vascular conditions |
DK62692D0 (es) | 1992-05-14 | 1992-05-14 | Novo Nordisk As | |
WO1994002497A1 (en) | 1992-07-15 | 1994-02-03 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Sulfo-derivatives of adenosine |
US5972991A (en) * | 1992-09-21 | 1999-10-26 | Allergan | Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
US5338430A (en) | 1992-12-23 | 1994-08-16 | Minnesota Mining And Manufacturing Company | Nanostructured electrode membranes |
US5443836A (en) | 1993-03-15 | 1995-08-22 | Gensia, Inc. | Methods for protecting tissues and organs from ischemic damage |
US5773423A (en) | 1993-07-13 | 1998-06-30 | The United States Of America As Represented By The Department Of Health And Human Services | A3 adenosine receptor agonists |
US5589467A (en) | 1993-09-17 | 1996-12-31 | Novo Nordisk A/S | 2,5',N6-trisubstituted adenosine derivatives |
WO1995011681A1 (en) | 1993-10-29 | 1995-05-04 | Merck & Co., Inc. | Human adenosine receptor antagonists |
US5620676A (en) | 1994-03-08 | 1997-04-15 | The United States Of America As Represented By The Department Of Health And Human Services | Biologically active ATP analogs |
EP0704215A3 (en) | 1994-06-02 | 1998-04-01 | Takeda Chemical Industries, Ltd. | Inhibitor of vascular permeability enhancer |
GB9414193D0 (en) | 1994-07-14 | 1994-08-31 | Glaxo Group Ltd | Compounds |
US5801159A (en) | 1996-02-23 | 1998-09-01 | Galileo Laboratories, Inc. | Method and composition for inhibiting cellular irreversible changes due to stress |
CN1164122A (zh) | 1996-03-01 | 1997-11-05 | 株式会社日立制作所 | 等离子处理机及其处理方法 |
AU2022497A (en) | 1996-03-13 | 1997-10-01 | Novo Nordisk A/S | A method of treating disorders related to cytokines in mammals |
WO1997033879A1 (en) | 1996-03-15 | 1997-09-18 | Merck & Co., Inc. | Compounds and methods for selectively inhibiting activation of the human a3 adenosine receptor |
US5789416B1 (en) | 1996-08-27 | 1999-10-05 | Cv Therapeutics Inc | N6 mono heterocyclic substituted adenosine derivatives |
TW528755B (en) | 1996-12-24 | 2003-04-21 | Glaxo Group Ltd | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives |
WO1998050047A1 (en) | 1997-05-09 | 1998-11-12 | Trustees Of The University Of Pennsylvania | Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists |
WO1999018949A1 (en) | 1997-10-15 | 1999-04-22 | Thomas Jefferson University | Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal |
WO1999020284A1 (en) | 1997-10-23 | 1999-04-29 | Trustees Of The University Of Pennsylvania | Methods for reducing ischemic injury of the heart via the sequential administration of monophosphoryl lipid a and adenosine receptor agents |
GB9723590D0 (en) | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
GB9723566D0 (en) | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
FR2775901B1 (fr) | 1998-03-13 | 2000-07-21 | Logeais Labor Jacques | Sels de cetoacides et de derives amines, et leur utilisation pour la preparation de medicaments |
GB9813535D0 (en) | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
EP1096975B1 (en) | 1998-07-16 | 2005-03-16 | The Trustees Of The University Of Pennsylvania | Use of a3 adenosine receptor antagonists in the manufacture of a medicament for reducing intraocular pressure |
WO2000023457A1 (en) | 1998-10-16 | 2000-04-27 | Pfizer Limited | Adenine derivatives |
IL127947A0 (en) | 1999-01-07 | 1999-11-30 | Can Fite Technologies Ltd | Pharmaceutical use of adenosine agonists |
US6232297B1 (en) | 1999-02-01 | 2001-05-15 | University Of Virginia Patent Foundation | Methods and compositions for treating inflammatory response |
KR100463694B1 (ko) | 1999-06-22 | 2004-12-29 | 씨브이 쎄러퓨틱스, 인코포레이티드 | 티오펜 a2a 수용체 작용제 |
US6214807B1 (en) | 1999-06-22 | 2001-04-10 | Cv Therapeutics, Inc. | C-pyrazole 2A A receptor agonists |
US6180615B1 (en) | 1999-06-22 | 2001-01-30 | Cv Therapeutics, Inc. | Propargyl phenyl ether A2A receptor agonists |
US6403567B1 (en) | 1999-06-22 | 2002-06-11 | Cv Therapeutics, Inc. | N-pyrazole A2A adenosine receptor agonists |
IL133680A0 (en) | 1999-09-10 | 2001-04-30 | Can Fite Technologies Ltd | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
GB9924361D0 (en) | 1999-10-14 | 1999-12-15 | Pfizer Ltd | Purine derivatives |
US6368573B1 (en) | 1999-11-15 | 2002-04-09 | King Pharmaceuticals Research And Development, Inc. | Diagnostic uses of 2-substituted adenosine carboxamides |
US6258793B1 (en) | 1999-12-03 | 2001-07-10 | Cv Therapeutics, Inc. | N6 heterocyclic 5′ modified adenosine derivatives |
GB9930071D0 (en) | 1999-12-20 | 2000-02-09 | Glaxo Group Ltd | Medicaments |
GB0003960D0 (en) | 2000-02-18 | 2000-04-12 | Pfizer Ltd | Purine derivatives |
US20010051612A1 (en) | 2000-02-23 | 2001-12-13 | Gloria Cristalli | 2-Thioether A2A receptor agonists |
US20030010454A1 (en) | 2000-03-27 | 2003-01-16 | Bailey Andrew D. | Method and apparatus for varying a magnetic field to control a volume of a plasma |
US6534651B2 (en) | 2000-04-06 | 2003-03-18 | Inotek Pharmaceuticals Corp. | 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof |
US6753322B2 (en) | 2000-06-06 | 2004-06-22 | Pfizer Inc | 2-aminocarbonyl-9H-purine derivatives |
US6921753B2 (en) | 2000-06-27 | 2005-07-26 | Pfizer Inc | Purine derivatives |
AR035651A1 (es) | 2000-07-28 | 2004-06-23 | Univ Madrid Complutense | Uso de derivados de indol para la manufactura de un medicamento para reducir la presion intraocular y una composicion |
DE60203702T2 (de) | 2001-01-16 | 2006-03-02 | Can-Fite Biopharma Ltd. | Verwendung eines adenosin-a3-rezeptor-agonisten zur hemmung der virenreplikation |
GB2372742A (en) | 2001-03-03 | 2002-09-04 | Univ Leiden | C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses |
EP1241176A1 (en) | 2001-03-16 | 2002-09-18 | Pfizer Products Inc. | Purine derivatives for the treatment of ischemia |
US20040204481A1 (en) | 2001-04-12 | 2004-10-14 | Pnina Fishman | Activation of natural killer cells by adenosine A3 receptor agonists |
US20030013675A1 (en) | 2001-05-25 | 2003-01-16 | Boehringer Ingelheim Pharma Kg | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases |
US7713946B2 (en) | 2002-07-11 | 2010-05-11 | Cv Therapeutics, Inc. | Partial and full agonists A1 adenosine receptors |
WO2003013683A1 (en) | 2001-08-08 | 2003-02-20 | Brown University Research Foundation | Methods for micronization of hydrophobic drugs |
WO2003029264A2 (en) | 2001-10-01 | 2003-04-10 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof |
MXPA04010285A (es) | 2002-04-18 | 2005-02-03 | Cv Therapeutics Inc | Metodo para tratar arritmias que comprende la administracion de un agonista de adenosina a1 con un bloqueador beta, bloqueador del canal de calcio o un glucosido cardiaco. |
EP2221054A1 (en) | 2002-04-30 | 2010-08-25 | Alcon, Inc. | CDK inhibitors for lowering intraocular pressure |
GB0216416D0 (en) | 2002-07-15 | 2002-08-21 | Novartis Ag | Organic compounds |
GB2412067B (en) | 2002-12-23 | 2007-11-14 | Global Cardiac Solutions Pty L | Organ preconditioning, arrest, protection, preservation and recovery (2) |
GB2436255B (en) | 2002-12-23 | 2007-11-28 | Global Cardiac Solutions Pty L | Organ preconditioning, arrest, protection, preservation and recovery |
CA2468664C (en) | 2003-06-03 | 2012-03-06 | Allergan, Inc. | Ketorolac tromethamine compositions for treating or preventing ocular pain |
CA2554716A1 (en) | 2004-01-22 | 2005-08-04 | Nitromed, Inc. | Nitrosated and/or nitrosylated compounds, compositions and methods of use |
PL1758596T3 (pl) | 2004-05-26 | 2011-01-31 | Inotek Pharmaceuticals Corp | Pochodne purynowe jako agoniści receptora adenozynowgo A1, oraz sposoby ich zastosowania |
CN101010085B (zh) | 2004-05-26 | 2012-12-26 | 伊诺泰克制药公司 | 嘌呤衍生物作为腺苷a1受体激动剂及其用法 |
CA2573682A1 (en) | 2004-07-12 | 2006-02-16 | Cv Therapeutics, Inc. | Process for the preparation of a1 adenosine receptor agonists |
EP1802277B1 (de) * | 2004-10-18 | 2010-01-13 | Polymun Scientific Immunbiologische Forschung GmbH | Liposomale zusammensetzung einen wirkstoff zur relaxierung glatter muskulatur enthaltend, die herstellung dieser zusammensetzung und deren therapeutische verwendung |
WO2007002139A2 (en) | 2005-06-22 | 2007-01-04 | The Trustees Of The University Of Pennsylvania | Neuroprotection of retinal ganglion cells |
WO2007064795A2 (en) | 2005-11-30 | 2007-06-07 | Inotek Pharmaceuticals Corporation | Purine derivatives and methods of use thereof |
WO2008029276A2 (en) | 2006-02-02 | 2008-03-13 | Allergan, Inc. | Compositions and methods for the treatment of ophthalmic disease |
US8784886B2 (en) | 2006-03-09 | 2014-07-22 | GlaxoSmithKline, LLC | Coating capsules with active pharmaceutical ingredients |
WO2007111954A2 (en) | 2006-03-23 | 2007-10-04 | Inotek Phamaceuticals Corporation | Purine compounds and methods of use thereof |
US8163737B2 (en) | 2006-06-13 | 2012-04-24 | Vertex Pharmaceuticals Incorporated | CGRP receptor antagonists |
EP2070518A2 (en) | 2006-07-25 | 2009-06-17 | Osmotica Corp. | Ophthalmic solutions |
CA2665616A1 (en) | 2006-10-06 | 2008-04-17 | The Trustees Of The University Of Pennsylvania | Effective delivery of cross-species a3 adenosine-receptor antagonists toreduce intraocular pressure |
MX2009004316A (es) | 2006-11-10 | 2009-05-05 | Basf Se | Nueva modificacion cristalina. |
CN101657212B (zh) | 2006-12-05 | 2014-03-19 | 皇家学习促进会/麦吉尔大学 | Trk受体调节剂的使用方法 |
JP2008266143A (ja) | 2007-04-16 | 2008-11-06 | Santen Pharmaceut Co Ltd | アデノシン誘導体を有効成分として含有する緑内障治療剤 |
EP2205071B1 (en) | 2007-10-11 | 2015-07-22 | Biogen MA Inc. | Lingo-1 antagonists and trkb agonists for use in the treatment of glaucoma |
WO2009076580A2 (en) | 2007-12-12 | 2009-06-18 | Thomas Jefferson University | Compositions and methods for the treatment and prevention of cardiovascular diseases |
CN101983062A (zh) | 2008-02-07 | 2011-03-02 | 吉利德帕洛阿尔托股份有限公司 | 提高abca-1的化合物及其用途 |
US8318167B2 (en) | 2008-11-13 | 2012-11-27 | The General Hospital Corporation | Methods and compositions for regulating iron homeostasis by modulation of BMP-6 |
EA024042B1 (ru) * | 2009-05-01 | 2016-08-31 | Инотек Фармасьютикалз Корпорейшн | Способ снижения внутриглазного давления у людей |
EA201200635A1 (ru) | 2009-10-26 | 2012-10-30 | Инотек Фармасьютикалз Корпорейшн | Глазной состав и способ его изготовления |
WO2011077435A1 (en) | 2009-12-22 | 2011-06-30 | Bar-Ilan University | Compositions and methods for reducing intraocular pressure |
AU2011203897B2 (en) | 2010-01-11 | 2016-11-17 | Inotek Pharmaceuticals Corporation | Combination, kit and method of reducing intraocular pressure |
US20110217262A1 (en) | 2010-03-05 | 2011-09-08 | Kornfield Julia A | Treatment of Ocular Surface Disorders by Increasing Conjunctival Vascular Permeability |
RS55617B1 (sr) | 2010-03-19 | 2017-06-30 | Inotek Pharmaceuticals Corp | Kombinovane kompozicije adenozinskih a1 agonista i inhibitora ugljene anhidraze za snižavanje intraokularnog pritiska |
CN102958526A (zh) * | 2010-03-19 | 2013-03-06 | 伊诺泰克制药公司 | 用于降低眼内压的腺苷A1激动剂与非选择性β-肾上腺素能受体阻断剂的组合型组合物 |
US8501708B2 (en) | 2010-03-26 | 2013-08-06 | Inotek Pharmaceuticals Corporation | Adenosine compounds and their use thereof |
US8476247B2 (en) * | 2010-03-26 | 2013-07-02 | Inotek Pharmaceuticals Corporation | Method of reducing intraocular pressure in humans |
-
2011
- 2011-01-11 AU AU2011203897A patent/AU2011203897B2/en not_active Ceased
- 2011-01-11 ME MEP-2017-11A patent/ME02608B/me unknown
- 2011-01-11 MX MX2012007661A patent/MX2012007661A/es active IP Right Grant
- 2011-01-11 PT PT117323097T patent/PT2523669T/pt unknown
- 2011-01-11 HU HUE11732309A patent/HUE030566T2/en unknown
- 2011-01-11 BR BR112012017106A patent/BR112012017106A2/pt not_active IP Right Cessation
- 2011-01-11 ES ES11732309.7T patent/ES2613698T3/es active Active
- 2011-01-11 DK DK11732309.7T patent/DK2523669T3/en active
- 2011-01-11 JP JP2012548226A patent/JP2013516495A/ja active Pending
- 2011-01-11 LT LTEP11732309.7T patent/LT2523669T/lt unknown
- 2011-01-11 WO PCT/US2011/020808 patent/WO2011085361A1/en active Application Filing
- 2011-01-11 KR KR1020127019681A patent/KR20120115344A/ko active IP Right Grant
- 2011-01-11 US US13/004,380 patent/US8877732B2/en not_active Expired - Fee Related
- 2011-01-11 SG SG2012047882A patent/SG182285A1/en unknown
- 2011-01-11 RS RS20170063A patent/RS55615B1/sr unknown
- 2011-01-11 EA EA201201011A patent/EA025415B1/ru not_active IP Right Cessation
- 2011-01-11 EP EP11732309.7A patent/EP2523669B1/en active Active
- 2011-01-11 CN CN201180005821.9A patent/CN102711771B/zh not_active Expired - Fee Related
- 2011-01-11 IN IN6592DEN2012 patent/IN2012DN06592A/en unknown
- 2011-01-11 PL PL11732309T patent/PL2523669T3/pl unknown
- 2011-01-11 SI SI201131077A patent/SI2523669T1/sl unknown
- 2011-01-11 CA CA2784908A patent/CA2784908A1/en not_active Abandoned
- 2011-01-11 SG SG10201502588UA patent/SG10201502588UA/en unknown
-
2012
- 2012-06-24 IL IL220604A patent/IL220604A/en not_active IP Right Cessation
- 2012-07-09 CL CL2012001912A patent/CL2012001912A1/es unknown
- 2012-08-10 CO CO12135136A patent/CO6571924A2/es not_active Application Discontinuation
-
2014
- 2014-10-17 US US14/517,509 patent/US9370530B2/en not_active Expired - Fee Related
-
2015
- 2015-12-04 JP JP2015237859A patent/JP2016040320A/ja active Pending
-
2016
- 2016-05-18 US US15/158,188 patent/US20160367586A1/en not_active Abandoned
-
2017
- 2017-01-04 HR HRP20170007TT patent/HRP20170007T1/hr unknown
- 2017-01-16 SM SM201700017T patent/SMT201700017B/it unknown
- 2017-01-23 CY CY20171100093T patent/CY1118510T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2613698T3 (es) | Combinación, kit y método de reducción de la presión intraocular | |
AR120961A2 (es) | Método y composición para tratar hipertensión ocular y glaucoma | |
PE20142456A1 (es) | COMPUESTOS DE OXAZOLIDIN-2-ONA Y USOS DE LOS MISMOS COMO INHIBIDORES DE LA PI3Ks | |
CY1122853T1 (el) | Σταθερα σκευασματα λινακλοτιδης | |
AU2016343803A8 (en) | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids | |
AR095341A1 (es) | Compuestos y usos para la modulación de hemoglobina | |
CO6331425A2 (es) | Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida | |
CO6620055A2 (es) | Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos | |
ECSP12011799A (es) | Compuestos de espiropiperidina y uso farmacéutico de los mismos | |
AR087471A1 (es) | Metodos de tratamiento de enfermedades degenerativas de la retina | |
AU2012307812A8 (en) | Ophthalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid | |
NZ628398A (en) | Stable preservative-free mydriatic and anti-inflammatory solutions for injection | |
UY29802A1 (es) | Análogos de la feniletilamina y su uso en el tratamiento del glaucoma | |
NZ597626A (en) | Bicyclic compound and use thereof for medical purposes | |
EA201070483A1 (ru) | Новые офтальмологические композиции | |
PH12014502465A1 (en) | Fluorinated bridged spiro[2.4]heptane derivatives as alx receptor agonists | |
RS54378B1 (en) | PROCEDURE FOR REDUCING EYE PRESSURE IN PEOPLE | |
WO2012066488A3 (en) | Bridged spiro[2.4]heptane ester derivatives | |
WO2004091630A8 (ja) | 眼に適用する疾患治療剤 | |
AR085616A1 (es) | Composicion farmaceutica inhalable que comprende glicopirrolato, uso | |
NI201200112A (es) | Combinacion triple para reduccion de presion intraocular | |
EA201301332A1 (ru) | ОФТАЛЬМОЛОГИЧЕСКИЙ ПРЕПАРАТ, СОДЕРЖАЩИЙ АНАЛОГ PGF2α | |
NZ630760A (en) | A method of providing ocular neuroprotection | |
EA201500224A1 (ru) | Стабильная фармацевтическая композиция, содержащая 8-[(3r)-3-амино-1-пиперидинил]-7-(2-бутин-1-ил)-3,7-дигидро-3-метил-1-[(4-метил-2-хиназолинил)метил]-1н-пурин-2,6-дион или его фармацевтически приемлемую соль | |
EA201490363A1 (ru) | Новые составы на основе (триметоксифениламино)пиримидинилов |